Orally Bioavailable Anti-HBV Dinucleotide Acyloxyalkyl Prodrugs

Citation

Coughlin, J. E., Padmanabhan, S., Zhang, G., Kirk, C. J., Govardhan, C. P., Korba, B. E., … & Iyer, R. P. (2010). Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. Bioorganic & medicinal chemistry letters, 20(5), 1783-1786.

Abstract

The acyloxyalkyl derivatives of a model anti-HBV dinucleotide were synthesized and evaluated as orally bioavailable prodrugs. Our studies have led to the identification of the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV).


Read more from SRI

  • An arid, rural Nevada landscape

    Can AI help us find valuable minerals?

    SRI’s machine learning-based geospatial analytics platform, already adopted by the USGS, is poised to make waves in the mining industry.

  • Two students in a computer lab

    Building a lab-to-market pipeline for education

    The SRI-led LEARN Network demonstrates how we can get the best evidence-based educational programs to classrooms and students.

  • Code reflected in a man's eyeglasses

    LLM risks from A to Z

    A new paper from SRI and Brazil’s Instituto Eldorado delivers a comprehensive update on the security risks to large language models.